Previous Close | 58.7 |
1-Year Change | 22.52% |
6-Months Change | 92.08% |
3-Months Change | 6.32% |
Moving Avg (50d) | 57.748 |
Moving Avg (200d) | 45.583 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.12B |
Beta (3-Years) | 0.96 |
Revenue Growth (ttm) | 223.63% |
Net Profit Margin (ttm) | -1900.65% |
Return On Assets (ttm) | -64.25% |
EPS (ttm) | -12.23 |
PE Ratio (ttm) | -4.8 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics. Wikipedia